During a median follow-up of eight years, the distant disease-free survival of screen-detected HER2 + and TN cancers was better than that of interval and nonparticipant cancers (age-adjusted HR = 0.16, 95% CI 0.03–0.81 and HR = 0.09, 95% CI 0.01–0.79, respectively). This evidence concerns the gene ERBB2 and cancer.